The US commercial drug development company Ore Pharmaceuticals has named Mark Gabrielson president and chief executive officer. He succeeds Charles Dimmler. Mr Gabrielson serves on the company's board of directors and was most recently managing general partner of the financial services firm p-Value Capital.
Mark Gabrielson named CEO of Ore Pharmaceuticals
The US commercial drug development company Ore Pharmaceuticals has named Mark Gabrielson president and chief executive officer. He succeeds Charles Dimmler. Mr Gabrielson serves on the company's board of directors and was most recently managing general partner of the financial services firm p-Value Capital.
More from Business
More from Scrip
Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.
IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.
CEO Rob Davis said the company is in pursuit of more deals as it looks to close the revenue gap looming from the loss of Keytruda in 2028.